Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus

Submitted by Sandra Infurna ([email protected]) on 2019-11-28T13:17:55Z No. of bitstreams: 1 JaciaraRamos_AlvaroBertho_etal_IOC_2005.pdf: 249028 bytes, checksum: 1b8458b7ca216f02f62f536bcc52ba4f (MD5)Approved for entry into archive by Sandra Infurna ([email protected]) on 2019-11-28T13:34:33Z (GMT) No. of bitstreams: 1 JaciaraRamos_AlvaroBertho_etal_IOC_2005.pdf: 249028 bytes, checksum: 1b8458b7ca216f02f62f536bcc52ba4f (MD5)Made available in DSpace on 2019-11-28T13:34:33Z (GMT). No. of bitstreams: 1 JaciaraRamos_AlvaroBertho_etal_IOC_2005.pdf: 249028 bytes, checksum: 1b8458b7ca216f02f62f536bcc52ba4f (MD5) Previous issue date: 2005Fundação Oswaldo Cruz. Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de Janeiro, RJ, Brasil.In this study the kinetics of humoral and cellular immune responses in first-time vaccinees and re-vaccinees with the yellow fever 17DD vaccine virus was analyzed. Flow cytometric analyses were used to determine percentual values of T and B cells in parallel to the yellow fever neutralizing antibody production. All lymphocyte subsets analyzed were augmented around the 30th post vaccination day, both for first-time vaccinees and re-vaccinees. CD3+ T cells increased from 30.8% (SE +/- 4%) to 61.15% (SE +/- 4.2%), CD4+ T cells from 22.4% (SE +/- 3.6%) to 39.17% (SE +/- 2%) with 43% of these cells corresponding to CD4+CD45RO+ T cells, CD8+ T cells from 15.2% (SE +/- 2.9%) to 27% (SE +/- 3%) with 70% corresponding to CD8+CD45RO+ T cells in first-time vaccinees. In re-vaccinees, the CD3+ T cells increased from 50.7% (SE +/- 3%) to 80% (SE +/- 2.3%), CD4+ T cells from 24.9% (SE +/- 1.4%) to 40% (SE +/- 3%) presenting a percentage of 95% CD4+CD45RO+ T cells, CD8+ T cells from 19.7% (SE +/- 1.8%) to 25% (SE +/- 2%). Among CD8+CD38+ T cells there could be observed an increase from 15 to 41.6% in first-time vaccinees and 20.7 to 62.6% in re-vaccinees. Regarding neutralizing antibodies, the re-vaccinees presented high titers even before re-vaccination. The levels of neutralizing antibodies of first-time vaccinees were similar to those presented by re-vaccinees at day 30 after vaccination, indicating the success of primary vaccination. Our data provide a basis for further studies on immunological behavior of the YF 17DD vaccine